Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 - DARPin® antiviral therapeutic candidates that are undergoing testing to target SARS-CoV-2 spike protein DARPin® therapeutics well suited for a pandemic setting due to multi-specific target binding, long half-life for sustained activity and highly scalable production, compared to monoclonal antibodies ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 27, 2021 / Molecular Partners AG (SIX:MOLN) and Novartis announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program for ensovibep, with Molecular Partners as sponsor of the studies.

Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

Basel, May 19, 2021 — Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2021 European Hematology Association (EHA) Virtual Congress. More than 110 abstracts, including Novartis-sponsored and investigator-initiated trials, will be presented at the meetings.

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis AG (NVS) Presents at Cardiovascular Update Broker Conference Call - (Transcript)

Amgen

The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS) Sandoz from selling a biosimilar of the drug in the U.S. until 2029. The justices turned away Novartis subsidiary Sandoz Inc's appeal of a lower court decision that upheld the validity of the patents.

Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report

Novartis AG (NYSE: NVS) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary acute myocardial infarction (AMI) population. Data were presented at the American College of Cardiology's virtual Scientific Session.

Novartis' Entresto Misses Primary Endpoint In Study After Heart Attacks

The stock price of Novartis AG (NYSE: NVS) increased by 1.01% as it went from $85.24 to $86.10 pre-market. This is why it happened.

NVS Stock: From $85.24 To $86.10 (1.01% Increase) Pre-Market Explanation

Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to one-year data, 6mg Beovu showed non-inferiority in change in best-corrected visual acuity from baseline compared to 2mg Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept).

Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study

Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of non-inferiority in change in best corrected visual acuity (BCVA) from baseline for Beovu 6 mg versus aflibercept 2 mg at year one1. In KESTREL, patients on Beovu 6 mg gained a mean of 9.2 letters versus 10.5 letters for patients on aflibercept 2 mg1. In KITE, patients on Beovu 6 mg gained a mean of 10.6 letters versus 9.4 letters for patients on aflibercept 2 mg1. These results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.

Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Pfizer

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during the first quarter of 2021, which ended on March 31.

The Eaton Vance Fund sells Novartis, Pfizer

AbbVie

British American Tobacco

Canadian Natural Resources

Chevron

Enbridge

Coca-Cola

Realty Income Corp

Pembina Pipeline

Sanofi

AT&T

TC Energy

Unilever

Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These International “Dividend Aristocrats” have raised dividends at least five straight years (Canadian), 10 years (European Union), or 25 years (U.S. companies).

Update: 91 'Top Dividend Stocks On Earth' For May

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

7 Pharmaceutical Stocks With Dividends in Hand

Novartis continues to be hurt by the pandemic, with damage to the ophthalmology and oncology markets continuing to drag on overall performance. Sandoz remains a troubled area, with a weak flu season in addition to pricing pressures accentuating problems with the business line.

Novartis Continues To Hurt From Ophthalmology And Oncology, Sandoz Drags As Well

Novartis AG's (NVS) CEO Vas Narasimhan on Q1 2021 Results - Earnings Call Transcript

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes

Why Novartis Missed Wall Street Q1 Estimates

Novartis earnings and revenue came in below first-quarter estimates, with the Swiss drug giant guiding to modest 2021 growth. Novartis stock edged lower.

Novartis Earnings, Sales Slightly Miss First-Quarter Views

Bayer AG

A Milan judge on Tuesday indicted the Italian units of Novartis and Bayer on charges of operating a scheme to cheat the regional public health service in Lombardy, legal and judicial sources said.

Italy judge sends Bayer, Novartis to trial in drugs fraud probe: sources

Novartis AG (NYSE: NVS) Q1 core net income dropped 4% Y/Y, as COVID-19 related lockdowns and disruptions around the globe hit demand. Novartis missed earnings and sales expectations as the pandemic hit demand for drugs for breast cancer, skin and eye conditions.

Novartis Q1 Earnings Take A Hit Amid COVID-19 Impact

CureVac B.V

Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference call on Tuesday.

Novartis CEO says could boost CureVac vaccine production, if needed

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%, missing analyst expectations, as COVID-19 related lockdowns and disruptions around the globe hit demand.

Novartis Q1 sales, profit miss analyst expectations amid COVID-19 impact

Basel, April 27, 2021 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said: “Novartis growth drivers and launches continued their strong momentum with double-digit growth for Entresto, Cosentyx, Oncology growth drivers and Zolgensma. We expect Sandoz performance to stabilize, in the near-term, after a challenging quarter. Our broad pipeline of novel medicines continued to progress, with the US approval of Entresto across the full spectrum of chronic heart failure and the positive readout for our radioligand therapy in prostate cancer. Our progress on building trust with society has been recognized by top rankings on the Access to Medicines Index and Sustainalytics. We remain confident in progressing our leading pipeline and delivering our growth outlook.”

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

Roche Holding AG

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.

Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra

Amazon

Alibaba

Salesforce

NIKE

These brand-name companies with $200 billion-plus market caps still have plenty of gas in the tank.

5 Megacap Stocks With 19% to 32% Upside, According to Wall Street

Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.

Novartis (NVS) Teams Up With Artios for Radioligand Therapies

Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets.

Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio

News for Novartis Stock (NVS)